Yiling Pharmaceutical Co., Ltd. was ranked as one of the top 20 most competitive pharmaceutical companies in China in 2022

Recently, under the guidance of the China Pharmaceutical Enterprise Management Association, the results of the "2022 China Top 20 Pharmaceutical Listed Companies Competitiveness" jointly launched by E drug manager Rong Media and Jun Consulting were announced
.
Among them, Yiling Pharmaceutical stood out from many listed pharmaceutical companies and won the list for the second consecutive year, ranking from 18 last year to 14
this year.
"China's Top 20 Pharmaceutical Listed Companies Competitiveness" has been selected for 14 consecutive sessions, through the "entrepreneur, capital, industry, resources and management" five dimensions of the enterprise to conduct a comprehensive assessment, to explore the comprehensive competitive strength, and can flexibly adapt to the industrial development cycle from the strategic level
.
In recent years, Yiling Pharmaceutical has entered the fast lane of development, ranking among the top 500 listed companies in China, the top 100 in China's brand value, the top 50 small and medium-sized board listed companies in China, and the top 20
listed companies in China 。 In the more than ten years since its listing in 2011, Ling Pharmaceutical has achieved leapfrog development in terms of capital competitiveness, and its operating income has increased from 1.
649 billion yuan to 10.
117 billion yuan in 2021, an increase of 513.
52%; Net profit increased from less than 315 million to 1.
344 billion in 2021, an increase of 326.
67%; Net assets increased from 1.
091 billion to 9.
618 billion, an increase of 781.
58%.

In the past 30 years since its establishment, Yiling Pharmaceutical has always adhered to the innovative development model of "theory-clinical-scientific research-industry-teaching", and built a new pattern
of pharmaceutical and health industry in which patented traditional Chinese medicine, chemical medicine and big health industry develop and promote each other.
Committed to the original and clinical application research of network disease theory, becoming the core competitiveness of the enterprise, under the guidance of the theory to develop 13 patented new Chinese medicine drugs, forming a unique product layout advantage, the company cardiovascular and cerebrovascular and cold respiratory disease drug field has been in the leading position
in the industry.
Listed companies are the source of the growth momentum of the real economy, the cornerstone of the healthy development of the capital market, the carrier of improving the modern enterprise system, the pioneer of fulfilling social responsibilities, and one of
the channels for investors to share the dividends of economic growth.
Improving the competitiveness of listed companies is a fundamental means to stabilize the main body of the market economy, and its significance is of great significance
.
Pharmaceutical enterprises disease health